STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1076 by analyst upside · 2026-08-14
ZNTL
Zentalis Pharmaceuticals, Inc.
Healthcare · Market Cap $297M · P/E 0x
ANALYST PRICE TARGET
+66.0%
implied upside to consensus target
Current Price $4.15
Consensus Target $6.89
Bull Target $10.0
Bear Target $4.0
Analysts Covering 9
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
4
Hold
5
Sell
0
52-Week Low $1.21
52-Week High $6.95
YTD Return +202.9%
FUNDAMENTALS
Market Cap $297M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.90
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.21
52-Week High $6.95
Current Price $4.15
Bear Target $4.0
Bull Target $10.0
● Now $4.15 ● Target $6.89
TRADING DATA
Avg Volume 1.2M
YTD Return +202.9%
Analyst Count 9
Consensus Hold
Upside to Target +66.0%
Last Updated 2026-08-14

ANALYST SUMMARY

Zentalis Pharmaceuticals, Inc. (ZNTL) is currently trading at $4.15 with a Wall Street consensus price target of $6.89, implying potential upside of 66.0% over the next 12 months. 9 analysts currently cover ZNTL, with a consensus rating of Hold - 44% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $10.0, while the most cautious has a target of $4.0.

ZNTL operates in the Healthcare sector with a market capitalisation of $297M. The stock is up 202.9% year-to-date and is currently trading near the upper end of its 52-week range of $1.21 – $6.95.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ZNTL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim - Reiterated
Buy → Buy 2026-04-10 62% win rate (8 calls)
Guggenheim reit
Buy → Buy 2026-03-27 62% win rate (8 calls)
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2025-11-12 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2025-08-07 Building track record
Wedbush reit
Neutral → Neutral 2025-05-15 Building track record
HC Wainwright & Co. reit
Buy → Buy 2025-05-15 31% win rate (48 calls)
Wedbush reit
Neutral → Neutral 2025-03-28 Building track record
HC Wainwright & Co. reit
Buy → Buy 2025-03-27 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
26
out of 100
Coverage depth
18/30
Consensus clarity
1/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →